An investigational drug for treating attention-deficit/hyperactivity disorder (ADHD) has demonstrated "significant reductions" in ADHD symptoms in new clinical trials. The drug, NRP104 (lisdexamfetamine dimesylate), is intended for use in children ages 6 to 12 and is currently under consideration for approval by the Food and Drug Administration.
Read moreFor over 100 years, the symptoms that constitute ADHD have been continuously refined by the scientific community. Many researchers note... Read more »
Questions are being raised about not only the long term effectiveness of ADHD medications but on the integrity of researchers in providing... Read more »
Drug interactions are when some substance negatively impact how a medication works. Medication can be affected in different ways: The... Read more »
A new experimental drug to treat attention-deficit/hyperactivity disorder (ADHD) has shown positive results in its latest clinical trial. The drug,... Read more »
The U.S. Food and Drug Administration has given second-round approval to NRP104, a new medication for attention-deficit/hyperactivity disorder... Read more »
Amid controversy surrounding the way the Food and Drug Administration (FDA) handled recent changes to labels for attention-deficit/hyperactivity... Read more »
The Food and Drug Administration (FDA) has issued an approval letter for NRP104, a new drug to treat attention-deficit/hyperactivity disorder (ADHD).... Read more »
Drugmaker Shire Plc has filed for approval from the Food and Drug Administration for a new attention-deficit/hyperactivity disorder (ADHD) drug.... Read more »